-
1
-
-
0022399581
-
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
-
Coussens L, Yangfeng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
-
(1985)
Science
, vol.230
, pp. 1132-1139
-
-
Coussens, L.1
Yangfeng, T.L.2
Liao, Y.C.3
-
2
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
3
-
-
33847147313
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
-
Wolff AC, Hammond MEH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
-
(2007)
J Clin Oncol
, vol.25
, pp. 118-145
-
-
Wolff, A.C.1
Hammond, M.E.H.2
Schwartz, J.N.3
-
4
-
-
79953311677
-
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care
-
Fabi A, Di Benedetto A, Metro G et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011; 17: 2055-2064.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2055-2064
-
-
Fabi, A.1
Di Benedetto, A.2
Metro, G.3
-
5
-
-
69849090104
-
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
-
Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009; 20: 1499-1504.
-
(2009)
Ann Oncol
, vol.20
, pp. 1499-1504
-
-
Simmons, C.1
Miller, N.2
Geddie, W.3
-
6
-
-
84874651590
-
Translating metastasis-related biomarkers to the clinic, progress and pitfalls
-
in press
-
Bidard FC PJ, Soria JC, Thiery JP. Translating metastasis-related biomarkers to the clinic, progress and pitfalls. Nat Rev Clin Oncol 2013; in press.
-
(2013)
Nat Rev Clin Oncol
-
-
Bidard, F.C.P.J.1
Soria, J.C.2
Thiery, J.P.3
-
7
-
-
4143094988
-
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
-
Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
-
(2004)
N Engl J Med
, vol.351
, pp. 781-791
-
-
Cristofanilli, M.1
Budd, G.T.2
Ellis, M.J.3
-
8
-
-
70449713638
-
Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
-
Liu MC, Shields PG, Warren RD et al. Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer. J Clin Oncol 2009; 27: 5153-5159.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5153-5159
-
-
Liu, M.C.1
Shields, P.G.2
Warren, R.D.3
-
9
-
-
77955514306
-
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer
-
Nakamura S, Yagata H, Ohno S et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010; 17: 199-204.
-
(2010)
Breast Cancer
, vol.17
, pp. 199-204
-
-
Nakamura, S.1
Yagata, H.2
Ohno, S.3
-
10
-
-
43049110616
-
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications
-
Nole F, Munzone E, Zorzino L et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19: 891-897.
-
(2008)
Ann Oncol
, vol.19
, pp. 891-897
-
-
Nole, F.1
Munzone, E.2
Zorzino, L.3
-
11
-
-
84857613654
-
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
-
Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-624.
-
(2012)
Ann Oncol
, vol.23
, pp. 618-624
-
-
Pierga, J.Y.1
Hajage, D.2
Bachelot, T.3
-
12
-
-
0036834995
-
Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer
-
Hayes DF, Walker TM, Singh B et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002; 21: 1111-1117.
-
(2002)
Int J Oncol
, vol.21
, pp. 1111-1117
-
-
Hayes, D.F.1
Walker, T.M.2
Singh, B.3
-
13
-
-
33751215245
-
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues
-
Meng S, Tripathy D, Shete S et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006; 103: 17361-17365.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 17361-17365
-
-
Meng, S.1
Tripathy, D.2
Shete, S.3
-
14
-
-
3042552362
-
HER-2 gene amplification can be acquired as breast cancer progresses
-
Meng SD, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101: 9393-9398.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 9393-9398
-
-
Meng, S.D.1
Tripathy, D.2
Shete, S.3
-
15
-
-
77956132705
-
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
-
Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; 21: 1765-1771.
-
(2010)
Ann Oncol
, vol.21
, pp. 1765-1771
-
-
Bidard, F.C.1
Mathiot, C.2
Degeorges, A.3
-
16
-
-
77955082633
-
All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer
-
Coumans FAW, Doggen CJM, Attard G et al. All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010; 21: 1851-1857.
-
(2010)
Ann Oncol
, vol.21
, pp. 1851-1857
-
-
Coumans, F.A.W.1
Doggen, C.J.M.2
Attard, G.3
-
17
-
-
79951909396
-
External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study
-
Kraan J, Sleijfer S, Strijbos MH et al. External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin Cytom 2010; 80B: 112-118.
-
(2010)
Cytometry B Clin Cytom
, vol.80 B
, pp. 112-118
-
-
Kraan, J.1
Sleijfer, S.2
Strijbos, M.H.3
-
18
-
-
79251548904
-
HER2-positive circulating tumor cells in breast cancer
-
Ignatiadis M, Rothe F, Chaboteaux C et al. HER2-positive circulating tumor cells in breast cancer. Plos One 2011; 10(6): e15624.
-
(2011)
Plos One
, vol.10
, Issue.6
-
-
Ignatiadis, M.1
Rothe, F.2
Chaboteaux, C.3
-
19
-
-
77951740458
-
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
-
Riethdorf S, Muller V, Zhang LL et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-2645.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2634-2645
-
-
Riethdorf, S.1
Muller, V.2
Zhang, L.L.3
-
20
-
-
84859158912
-
Neoadjuvant bevacizumab, trastuzumab and chemotherapy for primary inflammatory HER-2positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
-
Pierga JY, Petit T, Delozier T et al. Neoadjuvant bevacizumab, trastuzumab and chemotherapy for primary inflammatory HER-2positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012; 13: 375-384.
-
(2012)
Lancet Oncol
, vol.13
, pp. 375-384
-
-
Pierga, J.Y.1
Petit, T.2
Delozier, T.3
-
21
-
-
84877110619
-
Monitoring Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) during Neoadjuvant Combination of Trastuzumab and Bevacizumab with Chemotherapy in HER2 Overexpressing Inflammatory Breast Cancer (IBC): An Ancillary Study of BEVERLY 2 Multicenter Phase II Trial
-
San Antonio, TX
-
Pierga JY, Bidard FC, Petit T et al. Monitoring Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) during Neoadjuvant Combination of Trastuzumab and Bevacizumab with Chemotherapy in HER2 Overexpressing Inflammatory Breast Cancer (IBC): An Ancillary Study of BEVERLY 2 Multicenter Phase II Trial. San Antonio, TX: In San Antonio Breast Cancer Symposium, 2010, PD04-PD07.
-
(2010)
San Antonio Breast Cancer Symposium
-
-
Pierga, J.Y.1
Bidard, F.C.2
Petit, T.3
-
22
-
-
18544370747
-
A sample preparation and analysis system for identification of circulating tumor cells
-
Kagan M, Howard D, Bendele T et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002; 25: 104-110.
-
(2002)
J Clin Ligand Assay
, vol.25
, pp. 104-110
-
-
Kagan, M.1
Howard, D.2
Bendele, T.3
-
23
-
-
80455126047
-
Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients
-
Ligthart ST, Coumans FAW, Attard G et al. Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients. PLos One 2011; 6: e27419.
-
(2011)
PLos One
, vol.6
-
-
Ligthart, S.T.1
Coumans, F.A.W.2
Attard, G.3
-
25
-
-
84864085607
-
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression
-
Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 2601-2608.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2601-2608
-
-
Lindstrom, L.S.1
Karlsson, E.2
Wilking, U.M.3
-
26
-
-
84860356499
-
Biomarkers characterization of circulating tumour cells in breast cancer patients
-
Nadal R, Fernandez A, Sanchez-Rovira P et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012; 14(3): R71.
-
(2012)
Breast Cancer Res.
, vol.14
, Issue.3
-
-
Nadal, R.1
Fernandez, A.2
Sanchez-Rovira, P.3
-
27
-
-
77958557955
-
Molecular biomarker analyses using circulating tumor cells
-
Punnoose EA, Atwal SK, Spoerke JM et al. Molecular biomarker analyses using circulating tumor cells. Plos One 2010.
-
(2010)
Plos One
-
-
Punnoose, E.A.1
Atwal, S.K.2
Spoerke, J.M.3
-
28
-
-
84857088316
-
FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE (TM) platform
-
Mayer JA, Pham T, Wong KL et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE (TM) platform. Cancer Genet 2011; 204: 589-595.
-
(2011)
Cancer Genet
, vol.204
, pp. 589-595
-
-
Mayer, J.A.1
Pham, T.2
Wong, K.L.3
-
30
-
-
84878112286
-
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
-
November 6, [epub ahead of print], doi: 10.1007/s10555-012-9398-0
-
Bidard FC, Fehm T, Ignatiadis M et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Met Rev 2013, November 6, [epub ahead of print], doi: 10.1007/s10555-012-9398-0.
-
(2013)
Cancer Met Rev
-
-
Bidard, F.C.1
Fehm, T.2
Ignatiadis, M.3
|